Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 25

CNN

Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug, molnupiravir, might halve the risk of death or hospitalization from Covid-19.